TriSalus Life Sciences (TLSI) Capital Expenditures (2022 - 2026)

TriSalus Life Sciences' Capital Expenditures history runs 5 years deep, the most recent figure standing at $141000.0 for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 62.07% year-over-year to $141000.0 in Q1 2026; TTM through Mar 2026 was $122000.0, a 480.95% increase from a year earlier, with the FY2025 full-year figure at $68000.0, changed N/A from the prior year.
• Capital Expenditures advanced to $141000.0 in Q1 2026 per TLSI's latest filing, from -$809000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $857000.0 in Q3 2025 and bottomed at -$809000.0 in Q4 2025.
• The 5-year median for Capital Expenditures is $63000.0 (2024), against an average of $25571.4.
• Across the five-year window, Capital Expenditures surged 842.86% in 2024 and slumped 211.67% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at -$439000.0 in 2022, then surged by 184.74% to $372000.0 in 2023, then plunged by 179.3% to -$295000.0 in 2024, then tumbled by 174.24% to -$809000.0 in 2025, then soared by 117.43% to $141000.0 in 2026.
• Per Business Quant, the three latest TLSI Capital Expenditures figures stand at $141000.0 (Q1 2026), -$809000.0 (Q4 2025), and $857000.0 (Q3 2025).